Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 28, 2019

Health Canada approves Boehringer’s Ofev to slow SSc-ILD

Boehringer Ingelheim (Canada) has secured approval from Health Canada for its Ofev (nintedanib) to slow the rate of decline in patients suffering from systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Boehringer Ingelheim (Canada) has secured approval from Health Canada for its Ofev (nintedanib) to slow the rate of decline in patients suffering from systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Ofev is claimed to be the first and only treatment to slow the rate of decline in pulmonary function in patients with SSc-ILD.

ILD is considered to be a leading reason for death associated with SSc, representing 35% of all disease-related deaths. Around 40,000 people in Canada are estimated to be affected by systemic sclerosis.

The Canadian regulator has approved Ofev comes from results of SENSCIS, a double-blind, randomised and placebo-controlled, Phase III trial.

The study evaluated 576 patients across 32 countries, including Canada. The trial showed that Ofev slowed the loss of pulmonary function by 44% in patients with SSc-ILD compared to placebo, as measured by forced vital capacity (FVC) over 52 weeks.

Furthermore, the trial data indicated the safety and tolerability of Ofev in SSc-ILD patients. The FDA also approved nintedanib in SSc-ILD.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Ofev is already approved in over 70 countries to treat patients living with idiopathic pulmonary fibrosis (IPF).

Boehringer Ingelheim (Canada) medical and regulatory affairs vice president Dr Uli Brödl said: “With OFEV being the first therapy available in Canada to slow the rate of decline in pulmonary function for patients with SSc-ILD, it provides hope for these patients and their loved ones.

“This approval is supported by positive evidence from the Phase III SENSCIS study that showed that OFEV significantly slowed the progression of lung disease in this patient population.”

Boehringer Ingelheim reported net sales of around €17.5bn in 2018.

Its research and development expenditure was almost €3.2bn, corresponding to 18.1% of net sales. Boehringer established its Canadian headquarters in 1972 in Montreal, Quebec, now situated in Burlington, Ontario.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU